Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.

Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, Bosacki C, Jacquin JP, Levy A, Chauleur C, Magné N, Merrouche Y.

Am J Clin Oncol. 2015 Jun;38(3):272-7. doi: 10.1097/COC.0b013e3182979b27.

PMID:
23751320
2.

Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.

Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS.

Gynecol Oncol. 2001 Oct;83(1):89-94.

PMID:
11585418
3.

The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.

Guttmann DM, Li H, Sevak P, Grover S, Jacobson G, Feldman A, Rubin S, Chu C, Bhatia S, Elshaikh MA, Lin LL.

Int J Gynecol Cancer. 2016 Jan;26(1):141-8. doi: 10.1097/IGC.0000000000000561.

PMID:
26509850
4.

Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.

Sozen H, Çiftçi R, Vatansever D, Topuz S, Iyibozkurt AC, Bozbey HU, Yaşa C, Çali H, Yavuz E, Kucucuk S, Aydiner A, Salihoglu Y.

Aust N Z J Obstet Gynaecol. 2016 Apr;56(2):199-206. doi: 10.1111/ajo.12449. Epub 2016 Feb 18.

PMID:
26890292
5.

Uterine sarcoma-current management and experience from a regional cancer centre in North India.

Biswas A, Patel F, Kumar P, Srinivasan R, Bera A, Sharma SC, Rajwanshi A.

Arch Gynecol Obstet. 2013 Oct;288(4):873-82. doi: 10.1007/s00404-013-2843-7. Epub 2013 Apr 12.

PMID:
23580012
6.

A population-based series of ovarian carcinosarcomas with long-term follow-up.

Paulsson G, Andersson S, Sorbe B.

Anticancer Res. 2013 Mar;33(3):1003-8.

PMID:
23482773
7.

Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.

Seagle BL, Kanis M, Kocherginsky M, Strauss JB, Shahabi S.

Gynecol Oncol. 2017 Apr;145(1):71-77. doi: 10.1016/j.ygyno.2017.01.010. Epub 2017 Mar 15.

PMID:
28317560
8.

Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.

Garg G, Yee C, Schwartz K, Mutch DG, Morris RT, Powell MA.

Gynecol Oncol. 2014 May;133(2):242-9. doi: 10.1016/j.ygyno.2014.02.021. Epub 2014 Feb 19.

9.

Black race independently predicts worse survival in uterine carcinosarcoma.

Erickson BK, Doo DW, Zhang B, Huh WK, Leath CA 3rd.

Gynecol Oncol. 2014 May;133(2):238-41. doi: 10.1016/j.ygyno.2014.02.041. Epub 2014 Mar 6.

PMID:
24613675
10.

Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.

Bodner-Adler B, Bodner K, Obermair A, Czerwenka K, Petru E, Leodolter S, Mayerhofer K.

Anticancer Res. 2001 Jul-Aug;21(4B):3069-74.

PMID:
11712812
11.

Prognostic factors and adjuvant therapy in uterine carcinosarcoma.

Wu TI, Hsu KH, Huang HJ, Hsueh S, Chou HH, Tsai CS, Ho KC, Chao A, Chang TC, Lai CH.

Eur J Gynaecol Oncol. 2008;29(5):483-8.

PMID:
19051818
12.

Uterine sarcoma. Clinico-pathological characteristics and outcome.

Sait HK, Anfinan NM, El Sayed ME, Alkhayyat SS, Ghanem AT, Abayazid RM, Sait KH.

Saudi Med J. 2014 Oct;35(10):1215-22.

13.

Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.

Zhang C, Hu W, Jia N, Li Q, Hua K, Tao X, Wang L, Feng W.

Int J Gynecol Cancer. 2015 May;25(4):629-36. doi: 10.1097/IGC.0000000000000350.

PMID:
25633654
14.

A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Dickson EL, Vogel RI, Gehrig PA, Pierce S, Havrilesky L, Secord AA, Dottino J, Fader AN, Ricci S, Geller MA.

Gynecol Oncol. 2015 Nov;139(2):275-82. doi: 10.1016/j.ygyno.2015.09.002. Epub 2015 Sep 6.

15.

Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.

Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.

Int J Clin Oncol. 2016 Feb;21(1):168-76. doi: 10.1007/s10147-015-0859-7. Epub 2015 Jun 18.

PMID:
26084780
16.

Prognostic determinants in patients with uterine and ovarian carcinosarcoma.

Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG.

J Reprod Med. 2013 Jul-Aug;58(7-8):297-304.

PMID:
23947079
17.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. Review.

PMID:
25341582
18.

Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.

Huang CY, Tang YH, Chiang YC, Wang KL, Fu HC, Ke YM, Lau HY, Hsu KF, Wu CH, Cheng WF.

Gynecol Oncol. 2014 May;133(2):221-8. doi: 10.1016/j.ygyno.2014.02.010. Epub 2014 Feb 18.

PMID:
24556064
19.

Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.

Seagle BL, Kanis M, Strohl AE, Shahabi S.

Gynecol Oncol. 2016 Dec;143(3):636-641. doi: 10.1016/j.ygyno.2016.10.013. Epub 2016 Oct 20.

PMID:
27771166
20.

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.

Potikul C, Tangjitgamol S, Khunnarong J, Srijaipracharoen S, Thavaramara T, Pataradool K.

Asian Pac J Cancer Prev. 2016;17(4):1759-67.

Supplemental Content

Support Center